<DOC>
	<DOCNO>NCT00608803</DOCNO>
	<brief_summary>The study safety ZIO-201-T combination doxorubicin treatment advance cancer .</brief_summary>
	<brief_title>Phase 1 Study ZIO-201-T Combination With Doxorubicin Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Age ≥18 year Histological cytological documentation cancer Measurable disease Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 , 2 Ifosfamide doxorubicin naïve Life expectancy least 12 week Adequate bone marrow , liver , renal function , assess follow laboratory requirement conduct within 7 day prior dose : Hemoglobin &gt; 9.0 g/dL , Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 , Platelet count ≥100,000/mm3 , Total bilirubin &lt; 1.5×ULN , ALT AST ≤2.5×ULN , Partial thromboplastin [ PT ] INR/activated partial thromboplastin time [ PTT ] &lt; 1.5×ULN . Subjects therapeutically anticoagulated agent Coumadin ( warfarin sodium ) heparin allow provide prior evidence underlie abnormality coagulation parameter . If interaction study drug anticoagulant suspect , anticoagulation monitoring increase appropriate . Serum creatinine ≤ULN Written , informed consent must obtain potential subject prior conduct studyspecific procedure Male female subject must agree use adequate birth control measures/barrier control course trial . Women childbearing potential must pregnancy test perform within 7 day start treatment . Clinically evident congestive heart failure &gt; Class II New York Heart Association ( NYHA ) guideline Serious , clinically significant cardiac arrhythmia , define existence absolute arrhythmia , ventricular arrhythmia classify Lown III , IV , V History and/or sign active coronary artery disease/ischemia without angina pectoris Serious myocardial dysfunction define scintigraphically ( MUGA , myocardial scintigram ) determine absolute leave ventricular ejection fraction ( LVEF ) 45 % LVEF normal limit ( one criterion sufficient exclusion ) History HIV infection Prior nephrectomy history urinary tract obstruction Active , clinically serious infection require systemic antibacterial , antifungal , antiviral therapy Any major surgery within 3 week prior start treatment Metastatic brain meningeal tumor , unless subject &gt; 6 month definitive therapy negative imaging study within 4 week study entry . In addition , subject must undergo acute steroid therapy taper ( chronic steroid therapy acceptable , provide dose stable 1 month prior study start , follow screen radiographic study ) . History seizure disorder ( subject seizure related brain metastasis allow provide he/she seizurefree least 2 month meet criterion define inclusion subject brain metastasis ) Previous malignancy ( except cervical carcinoma situ , adequately treat basal cell carcinoma , superficial bladder tumor [ Ta , Tis , &amp; T1 ] malignancy curatively treat &gt; 3 year prior entry ) Pregnancy lactation Substance abuse medical , psychological , social condition may interfere subject 's participation study evaluation study result Any condition unstable could jeopardize safety subject his/her compliance protocol requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>